Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.

Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.

The company impresses investors, but money’s running short.

But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.

Menin, BTK and a Car-T skirmish featured over the ASH weekend.

Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.